⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245451 | 0.70 | — | — | |
| SCHEMBL22265814 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL34468684 | 0.67 | — | — | |
| SCHEMBL42544 | 0.67 | — | — | |
| SCHEMBL31424 | 0.67 | — | — | |
| SCHEMBL8468917 | 0.65 | — | — | |
| SCHEMBL2781 | 0.64 | — | — | |
| SCHEMBL573159 | 0.64 | — | — | |
| SCHEMBL2552636 | 0.64 | — | — | |
| SCHEMBL28335 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | claimed |
| WO-2023087632-A1 | ANTI-INFLAMMATORY ANALGESIC COMPOUND AND USE THEREOF | 江苏新元素医药科技有限公司 | 2023-05-25 | — | — | WO | claimed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | claimed |
| CN-114656429-A | Anti-inflammatory analgesic compound and application thereof | 江苏新元素医药科技有限公司 | 2022-06-24 | — | — | CN | claimed |
| EP-3860984-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | claimed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | claimed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | claimed |
| EP-3728214-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2020-10-28 | — | — | EP | claimed |
| CN-111727185-A | Substituted N-heterocyclyl-and N-heteroaryltetrahydropyrimidines and their salts and their use as herbicidal active substances | 拜耳公司 | 2020-09-29 | — | — | CN | claimed |
| WO-2020070088-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-09 | — | — | WO | claimed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003091232-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | WO | claimed |
| US-6579873-B2 | Treatment of inflammation, arthritis, bone disorders, respiratory system disorders | PHARMACIA CORPORATION | 2003-06-17 | — | — | US | claimed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | claimed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | claimed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | claimed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | claimed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | claimed |
| US-5932576-A | USEFUL FOR TREATING P38 KINASE MEDIATED DISORDERS SUCH AS ATHEROSCLEROSIS, RHEUMATIOD ARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHERS | G. D. SEARLE & COMPANY (US) | 1999-08-03 | — | — | US | claimed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |